Previous Close | 11.51 |
Open | 11.46 |
Bid | 0.00 x 900 |
Ask | 0.00 x 900 |
Day's Range | 11.40 - 11.85 |
52 Week Range | 7.40 - 18.93 |
Volume | |
Avg. Volume | 499,798 |
Market Cap | 628.14M |
Beta (5Y Monthly) | 1.08 |
PE Ratio (TTM) | 24.53 |
EPS (TTM) | 0.48 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.00 |
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWI
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.